Osteoarthritis management: Does the pharmacist play a role in bridging the gap between what patients actually know and what they ought to know? Insights from a national online survey

Andrew J. McLachlan BPharm (Hons), PhD, Professor1 | Peter R. Carroll BPharm, MSc, PhD, FPS, Professor1,3 | David J. Hunter MBBS (Hons), MSc (Clin Epi), MSpMed, PhD, FRACP (Rheum), Professor2 | Tom A. N. Wakefield BSc (Hons1 Stat, Math), BCom (Econ), GradCert (DataSci), Senior Statistician4 | Rodney Stosic BSc, PhD, MBA, Head of Medical Affairs - Consumer Healthcare5

1Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia
2Department of Rheumatology, Royal North Shore Hospital, The University of Sydney, St. Leonards, New South Wales, Australia
3Department of Clinical Pharmacology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia
4FiftyFive5, Ultimo, New South Wales, Australia
5Bayer Australia Pty., Ltd., Pymble, New South Wales, Australia

Abstract

Background: Guidelines encourage engagement in self-care activities for osteoarthritis (OA), but there are gaps in consumers' knowledge about suitable choices for self-care. Community pharmacists are in an ideal position to contribute to OA management through screening and supporting evidence-based pain management choices. Prior research established an association between health literacy and advice-seeking and appropriateness of analgesics choices (both lower in participants with limited health literacy) amongst people living with OA. This article explores the implications of these data for pharmacists in OA management.

Methods: A national online survey was conducted amongst 628 adults aged 45–74 years, currently residing in Australia, with self-reported symptoms of OA. All data were collected using a customized online questionnaire, which was completed only once. ‘Self-reported symptoms of OA’ was based on six validated screening questions to identify people with OA without a formal clinical diagnosis.

Results: Respondents matched the typical profile of people diagnosed with OA; more than half were female (56%), knees (59%) and hips (31%) were the primary affected joints and 74% were either overweight or obese. Self-identification of OA was limited (41%). Overall, 38% self-managed their pain, and limited health literacy was associated with less advice-seeking. Efficacy and ease of use were the main reasons cited for prompting use across all classes of nonprescription analgesic, with

Health Expectations. 2022;25:936–946.
less than 20% reporting recommendation from a pharmacist. Participants were managing their pain with an average of 1.74 (95% confidence interval: 1.60–1.88) analgesics, but 73% reported inadequate pain relief and 54% had disrupted sleep. **Conclusion:** Our findings highlight three key themes: lack of self-identification of OA, suboptimal pain relief and limited use of the community pharmacist as a source of management advice. Equipping community pharmacists with tools to identify OA could bridge this gap. More research is needed to determine if it will improve consumers’ ability to appropriately manage OA pain.

**Patient or Public Contribution:** Consumers living with OA contributed to the study outcomes, reviewed the survey questionnaire for face validity and advised on plain language terminology.

**KEYWORDS**
analgesics, Australia, community pharmacy, health literacy, osteoarthritis, recommendations, screening

1 | INTRODUCTION

Osteoarthritis (OA), a complex, chronic health problem, is associated with significant burden. Australian National Health Survey data collected in 2017–2018 estimated that one-fifth of Australians over the age of 45 years had OA. Global data predict OA to become one of the most prevalent diseases in populations from high-income countries, with the suggestion that by 2032, almost 30% of the population aged 45 years are expected to have doctor-diagnosed OA.

Current OA management focuses on symptomatic relief and reducing disability progression, via a combination of lifestyle, nonpharmacological, pharmacological and surgical approaches tailored to the needs of the individual. To further facilitate lifestyle and nonpharmacological approaches, established guidelines encourage engagement in self-care activities. Proposed strategies to mitigate the future burden of OA suggest that there is a need for ‘better awareness, especially of the risk factors, and early diagnosis and treatment of OA together with the improvement of healthcare infrastructure for managing the increasing number of patients with OA.’

Health literacy has been highlighted as an important component of patient engagement self-management strategies. There are negative relationships between health literacy and diagnosis comprehension, health outcomes and use of healthcare services, and limited health literacy is identified as an obstacle to accessing primary care services.

Adequate health literacy has previously been shown to be integral to patients’ decisions to adopt and engage with OA self-management strategies. However, data exploring this issue from the perspective of the patient are limited. A recent survey, conducted amongst adults with self-reported symptoms of OA, investigated the participants’ perceptions of pain and their use of self-management strategies for pain relief. The study reported a significant association between health literacy and the appropriate selection of recommended self-management strategies and highlighted participants suboptimal knowledge about suitable pain relief choices. Recognizing that the pharmacist is well placed to provide counselling to help improve patients’ knowledge about and correct use of medicines, this paper explores this study, focusing on the findings of relevance to the community pharmacist.

2 | METHODS

The methods have been published in detail elsewhere. Briefly, a national online survey was conducted amongst adults aged 45–74 years, currently residing in Australia, with self-reported symptoms of OA. The cohort was derived from an Australian accredited research-only online panel (Dynata). Participants were incentivized through the receipt of panel points and provided informed consent before commencing the survey. All data were self-reported and collected using a customized online deidentified questionnaire, which was completed only once. Ethical clearance was received (Bellberry Human Research Ethics Committee; Eastwood, SA, Australia: HREC2020-05-494-A1).

The key study eligibility criterion ‘self-reported symptoms of OA’ was based on six screening questions designed specifically to capture a representative population of people with OA without seeking formal evidence of a clinical diagnosis. Three of the screening questions (1) ‘age 45 years or over’, (2) ‘has activity-related joint pain’ and (3) ‘has either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 min’ were based on the definition of clinically diagnosed OA supported by the National Institute for Health and Clinical Excellence Guidelines for OA and the Royal Australian College of General Practitioners guideline for the management of hip and knee OA. Three
additional screening questions related to (4) ‘no trauma in the previous 3 months’, (5) ‘a minimum duration of pain (>3 months)’ and (6) ‘a minimum pain intensity (>3/10 on an 11-point visual analogue scale [VAS])’ further defined current OA and helped to rule out other causes.29

The remainder of the questionnaire comprised validated tools to evaluate health literacy,21–23 health-related quality of life,26,27 OA symptoms, impact and comorbidities,28–36 medication beliefs and adherence37–39 and other questions developed empirically through review of the literature.22,40–42 A group of consumers living with OA contributed to selecting the study outcomes, reviewed the survey questionnaire for face validity and provided advice on plain language terminology. Literature-based quality indicators4,5,43 were predefined in the protocol based on a traffic light system (green, amber, red) and used to categorize the appropriateness of the respondents’ choices for OA self-care. Within this system, green represented core strategies and/or those with a strong recommendation or conditional recommendation (Levels 1A, 1B, 2), amber strategies with a conditional recommendation neutral or against (Levels 3, and 4B) and red strategies, which are not recommended (Levels 4A and 5).

The primary analysis population comprised all participants who fulfilled the criteria for self-reported symptoms of OA. Four pre-specified, but not mutually exclusive, subpopulations were defined to account for differences in management recommendations amongst participants with comorbidities: OA and no comorbidity, OA plus gastrointestinal comorbidities, OA plus cardiovascular comorbidities and OA plus widespread pain and/or depression.

The average proportion of green, amber and red management strategies that a respondent was using provided a numeric measure of the appropriateness of their self-care choices, and health literacy was measured using a categorical variable that classified each person’s health literacy into low (score ≤ 32), moderate (score: 33–38) or high (score > 38) using validated cut-off criteria.25,44 For each participant, the number of appropriate strategies (based on the traffic light system, green/amber/red) they reported using were first summed and then divided by the total number of strategies recommended for their level of comorbidity. A score of 0 was used to indicate that they are not using any green/amber/red strategies, a score of 0.5 was used to indicate that they are using half of the green/amber/red strategies and a score of 1 was used to indicate that they were using all green/amber/red strategies. A higher score was, therefore, indicative of more appropriate choices for green strategies, but less appropriate choices for red strategies. A one-way multivariate analysis of variance test, with the three management appropriateness metrics as the dependent variables and health literacy as the independent variable, was used to test for statistical significance.

Baseline variables and outcome measures were analysed among the primary and subpopulations. Continuous variables were summarized descriptively, and differences were analysed using two-sample t-tests and categorical variables were summarized as contingency tables using sample sizes and percentages with two-sided 95% confidence intervals (CIs) and analysed using two-sample z-tests. A p-value less than .05 was considered significant. All statistical analyses were generated using Q-research software (Ver 5.9.7.0; Displayr).

3 | RESULTS

Out of the total pool of respondents (N = 6800), 6348 were in the target age range (45–74 years) and answered all screening questions. Of these, 697 (10%) fulfilled all of the screening criteria for self-reported OA, and 69 withdrew consent, leaving a population of 628 eligible participants (Table 1). Detailed demographics for the primary and secondary populations are provided in Table S1.

3.1 | Health literacy and appropriateness of management choices

The proportions of participants classified as having low, moderate or high health literacy were similar in the overall population and the secondary analysis populations. A significantly higher proportion of females were categorized as having high health literacy than were males (Table 1). The primary endpoint analysis showed evidence of a statistically significant interaction between health literacy and overall appropriateness of management strategies (p < .001).18

3.2 | Baseline characteristics, pain symptoms and self-recognition of OA

The majority of participants (82.5%) were nonsmokers; almost three-quarters were overweight or obese and health-related quality of life was generally good (Table 2). Participants reported having current pain in 4.1 joints; the most frequent location of joint pain was in the lower body, and the majority (82.1%) had been experiencing joint pain for more than a year (Table 2).

All participants fulfilled the study eligibility criterion for ‘self-reported symptoms of OA’, but when presented with a list and asked to indicate if they had any current health conditions or were taking medications/receiving treatment for current conditions, 40.8% self-identified OA and, amongst those, only half (52.0%) reported currently taking medication and/or receiving treatment for OA. Women, participants aged 55–74 years and those who had experienced pain for longer (5+ years) were more likely to self-identify as having OA (Figure 1).

Participants reported an average pain intensity of 5.9 (95% CI: 5.8–6.0) at its worst and 4.7 (95% CI: 4.6–4.9) in the past 7 days, on a scale of 0–10. The corresponding data from 0 to 100 VAS scales used in validated clinical tools for hip (HOOS-12)28,29 and knee (KOOS-12)28,30 OA were similar: average hip pain intensity (64.0; 95% CI: 62.1–65.9) and average knee pain intensity (63.5; 95% CI: 61.9–65.1). Participants were managing their pain with an average of 1.44 (95% CI: 1.32–1.57) self-care activities, 1.74 (95% CI: 1.60–1.88) analgesics and 1.01 (95% CI: 0.90–1.12) complementary
The majority (72.9%) reported inadequate pain relief (VAS score $\geq 4$) in the past week and over half (54.1%) had disrupted sleep, with 10.7% reporting disrupted sleep on 3 or more nights each week in the past month.

### Resources used for pain management

The general practitioner/family doctor was the main healthcare provider from whom advice about current pain management was received (Table 3). Almost 4 out of 10 (37.9%) participants reported that they were not receiving help from anyone to manage their pain.
Table 3, and a similarly high proportion (44.9%) reported that they used the internet search as a source for advice or information about how to manage their joint pain. There was an overall association between health literacy and advice seeking, but the differences were not statistically significant. When compared to participants classified as having moderate (64%) and high (63%) health literacy, fewer (54%) participants with low health literacy reported having sought any advice for pain management (Table 3).

3.4 | Awareness, choice and use of nonprescription analgesics

There were high levels of awareness of different classes of analgesics that could be purchased without a prescription, and paracetamol was reported to be the most frequently used of these analgesics (Table 4). The two main sources of recommendation for use of nonprescription analgesics were the family doctor and the pharmacist, and these healthcare professionals prompted current use in around half of the respondents. Around 30% of participants reported that no one had recommended the use of their current analgesic; efficacy and ease of use were the main reasons cited for prompting use across all classes of non-prescription analgesics (Table 4). Rates of adherence were suboptimal; less than two in five participants were found to have a high level of adherence irrespective of the nonprescription analgesic being used. Around three-quarters of participants reported being satisfied, or highly satisfied, with the pain relief achieved from their analgesic (Table 4). The pharmacy was the primary place to purchase non-prescription analgesics, accounting for 75%–80% of purchases depending on the analgesic; with 25%–35% of purchases being made in the supermarket; some people reported purchasing from both places.

4 | DISCUSSION

A recent online survey amongst adults with self-reported symptoms of OA has identified limited self-recognition of OA, suboptimal knowledge about suitable choices for OA self-care and a statistically significant interaction between health literacy and overall appropriateness of management strategies. Further exploration of this data has identified a high level of self-reliance for pain management advice—38% of participants were not receiving help from anyone and...
45% were using the internet as a source of advice—an association between not seeking advice and inadequate health literacy, and ease of use as the key driver prompting the trial of a nonprescription analgesic.

The study results are strengthened by the use of a wide selection of validated assessment tools and the large prospective sample of more than 600 respondents but limited by the potential for bias from the online survey methodology. With approximately 19% of the population anticipated to fulfill the eligibility criteria, it was expected that 3156 respondents would be required to ensure a minimum sample size of 600 participants for statistical analysis. A number of patients (n = 2987) failed study entry because they had reported an injury within the last 3 months. Excluding these respondents, 21% of the sample would have qualified for the survey, closely matching the original sample estimates and supporting its representativeness. Participant characteristics were consistent with the profile of patients with OA, including gender, age distribution, the location of the joints affected and the presence of comorbidities. Furthermore, demographic data, including ethnicity, geographical location, marital status, education, income and medical insurance, demonstrated comparable representativeness to the Australian population.

Others have suggested that patients with early knee OA may lack sufficient knowledge to recognize their condition. Our results corroborate this, and suggest that a lack of self-recognition of OA may also lead to poor self-management. Despite meeting guideline-endorsed clinical criteria for a diagnosis of OA, three out of every five participants did not self-identify that they had OA and the majority (72%) reported inadequate pain relief in the past week. Amongst the nonprescription analgesics currently being used, paracetamol was most widely used (47% of participants), but 3 in every 10 participants reported low satisfaction with the outcomes. While historically paracetamol has been regarded as a first-line analgesic for the management of OA pain, there is high-quality evidence that it provides only modest pain relief for people with knee or hip OA (mean pain relief on a 0–10 scale of 0.3 points; 95% CI: –0.6 to –0.1 point decrease in the pain score). This is below the minimum clinically important difference, which is typically defined as 10% or a 1-point change on a 0–10 point scale. Current guidelines for the management of hip and knee OA provide a neutral recommendation for paracetamol and topical nonsteroidal anti-inflammatory drugs (NSAIDs) and a conditional recommendation for the use of oral NSAIDs.

Overall, two in every five respondents reported that they were managing their joint pain on their own. Participants reported high levels of awareness of different classes of nonprescription analgesics. This may explain why only 17% had sought advice from the community pharmacist specifically about the use of this class of analgesics to manage their joint pain, and also why features such as efficacy, convenience and ease of use were cited more frequently than was pharmacist recommendation as a reason for having selected a particular analgesic.
The medicines scheduling in Australia are such that some medicines are permitted to be purchased in general sales outlets, while others are restricted to purchase only in pharmacies or after receipt of pharmacist advice. The nonprescription analgesics named in the survey can be purchased in either the pharmacy or the supermarket, but there are pack size restrictions (less than 20 tablets) on the products available in the supermarket. Place of purchase data show that the pharmacy is still the main place for purchase analgesics, but

### TABLE 4  Awareness, choice and use of nonprescription analgesics

|                      | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|----------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **N**                | 297         | 120        | 41                                | 85           | 100                 |

#### Awareness and use

|                        | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|------------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **Currently using**    | 47.3%       | 19.1%      | 6.5%                              | 13.5%        | 15.9%               |
| **Used within the last year** | 25.2%       | 23.1%      | 13.4%                             | 20.1%        | 18.5%               |
| **Used more than a year ago** | 10.8%       | 18.0%      | 9.4%                              | 16.4%        | 14.5%               |
| **Aware of, but not tried** | 14.5%       | 31.1%      | 44.1%                             | 34.1%        | 33.1%               |

#### Reasons prompting use

|                        | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|------------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **The doctor prescribed it** | 33.7%       | 23.3%      | 19.5%                             | 21.2%        | 22.0%               |
| **A pharmacist recommended it** | 18.9%       | 18.3%      | 26.8%                             | 32.9%        | 24.0%               |
| **Effective pain relief** | 41.8%       | 52.5%      | 46.3%                             | 41.2%        | 40.0%               |
| **Easy to use**        | 39.1%       | 34.2%      | 41.5%                             | 38.8%        | 42.0%               |
| **Convenience**        | 24.2%       | 21.7%      | 26.8%                             | 18.8%        | 23.0%               |

#### Sources of recommendation

|                        | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|------------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **General practitioner** | 57.9%       | 43.3%      | 43.9%                             | 43.5%        | 42.0%               |
| **No one**             | 28.3%       | 33.3%      | 24.4%                             | 27.1%        | 23.0%               |
| **Pharmacist**         | 12.5%       | 15.8%      | 17.1%                             | 12.9%        | 16.0%               |
| **Pain specialist/orthopaedic surgeon** | 8.1%         | 7.5%       | 12.2%                             | 4.7%         | 2.0%                |
| **Friend/family member** | 8.8%        | 11.7%      | 14.6%                             | 15.3%        | 19.0%               |
| **Allied healthcare provider\(^b\)** | 6.1%        | 2.5%       | 12.2%                             | 10.6%        | 12.0%               |
| **Other**              | 1.0%        | 2.5%       | 4.9%                              | 4.7%         | 1.0%                |

#### Adherence\(^c\)

|                        | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|------------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **Low**                | 19.5%       | 20.8%      | 24.4%                             | 27.1%        | 24.0%               |
| **Medium**             | 59.6%       | 56.7%      | 61.0%                             | 55.3%        | 57.0%               |
| **High**               | 20.9%       | 22.5%      | 14.6%                             | 17.6%        | 19.0%               |

#### Satisfaction\(^d\)

|                        | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|------------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **Low**                | 29.3%       | 21.7%      | 12.2%                             | 24.7%        | 25.0%               |
| **Medium**             | 44.8%       | 50.0%      | 43.9%                             | 50.6%        | 44.0%               |
| **High**               | 25.9%       | 28.3%      | 43.9%                             | 24.7%        | 31.0%               |

#### Purchased from where?

|                        | Paracetamol | Oral NSAID | Paracetamol/ibuprofen combination | Topical NSAID | Other topical\(^a\) |
|------------------------|-------------|------------|-----------------------------------|--------------|---------------------|
| **Pharmacy/online pharmacy** | 77.8%       | 76.7%      | 73.2%                             | 82.4%        | 84.0%               |
| **Supermarket**        | 34.3%       | 35.8%      | 29.3%                             | 30.6%        | 25.0%               |

Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.

\(^a\)Topical pain relief preparations include arnica, camphor, menthol, methyl salicylate, capsaicin.

\(^b\)Allied health care provider = physiotherapist, chiropractor, osteopath, massage therapist

\(^c\)Adherence was assessed using the Morisky Medication-Taking Adherence Scale; adherence was calculated as follows, score of 4 = high, 3 or 2 = intermediate, and 1 or 0 = low.

\(^d\)Satisfaction was assessed using a categorical scale and grouped for presentation; high = extremely/very satisfied, intermediate = satisfied, low = somewhat satisfied /not at all satisfied.
up to 35% of users of nonprescription analgesics reported purchasing from a supermarket. The main reasons for choice of analgesic were efficacy and ease of use, and many respondents did not seek any advice on recommendation. This might imply that a proportion of respondents had been using whatever analgesic they had available rather than seeking out advice for an analgesic specifically for their joint pain. Further research would be needed to better define these parameters and to determine if there is any correlation between analgesic choice based on convenience and suboptimal pain control.

Adequacy of health literacy is associated with a patient’s ability to access, understand, appraise and interpret health information. Patients lacking these core competencies in health literacy are limited in their ability to apply information to their current medical or clinical issues, their risk factors for health and to determinants of health in their social and physical environments. All of these can impact decision-making in relation to healthcare needs, disease prevention and health promotion. Having adequate health literacy has been highlighted as a key factor in patients’ decisions to adopt and engage with OA self-management strategies. Health literacy has the potential to influence the appropriateness of self-care strategies and could therefore impact outcomes achievable via patient-directed OA management. The primary endpoint analysis from the study highlights this to be of particular relevance. Knowledge about suitable choices of analgesics for joint pain management was suboptimal. Use of green (evidence levels 1A, 1B and 2) analgesics was low across all three health literacy groups, although there was a numerical trend for the use of more green strategies with increasing health literacy classification. However, amongst the red (evidence levels 4A, 5) analgesics, there was also a numerical trend for the use of more of these strategies with increasing health literacy classification, suggesting that higher health literacy does not always translate into appropriate choices. Amongst participants classified as having high health literacy, use of supplements and/or combinations of analgesics for which the evidence base is either insufficient or unsupported (per the quality indicators predefined in our protocol) was a key component of these poor choices.

It has previously been suggested that there is a need for interventions that improve patients’ knowledge of OA and their ability to self-manage it, whilst tailoring management to the needs of the individual patient. However, this only becomes practical after the patient had been diagnosed. Many patients view musculoskeletal pain as a normal part of ageing. It is deemed to be of less importance within the hierarchy of conditions for which healthcare support is sought, with lack of natural resolution of pain cited as a reason for seeking initial healthcare input.

Community pharmacists are frontline, accessible healthcare professionals. It is already established that screening for chronic diseases in a community pharmacy can facilitate earlier diagnosis and identification of risk factors. Through their traditional role as dispensers of medications and providers of medicines and health advice, community pharmacists have become a trusted source of information and are positioned to provide patients with healthcare support. In recent years, the role of the community pharmacist has expanded, such that it now incorporates medication assessment and patient education as well as screening and management advice for a number of conditions with demonstrated improvements in patient outcomes. Prior research has established that, when provided with a simple screening questionnaire, community pharmacists are able to identify more than 80% of patients with knee pain who have undiagnosed knee OA. Canadian guidelines suggest that the community pharmacist can screen patients aged 45 years or older for symptoms of OA, then triage these customers by providing education, treatment recommendations in accordance with current OA guidelines and referral to other healthcare professionals as appropriate. In this study, early OA screening was based on guidelines supporting that OA can be diagnosed clinically without the need for diagnostic tests or imaging through the use of three criteria (age 45 years or older, the presence of activity-related joint pain and no morning joint-related stiffness or stiffness that lasts less than 30 min). Our survey utilized these three screening criteria and then expanded this with three additional questions (minimum duration of pain > 3 months, minimum pain intensity > 3/10 and no recent trauma) to better help to establish current OA and rule out other causes, and has demonstrated it to be an effective screening tool for identifying early OA.

However, our research highlights a gap in the use of the community pharmacist as a resource for advice about OA pain and its management. The data demonstrate that overall, only 3.5% of respondents had sought pain management advice from the pharmacist. In addition, there was an association with health literacy, with the data showing that more people with low health literacy reported not seeking pain relief advice from anyone. It is vital that pharmacists recognize the limitations of low health literacy, in particular, how they relate to the lack of willingness of a consumer to proactively seek advice and to be able to act upon that advice. Prior research identified an association between lack of dialogue and health literacy and has called for increased engagement between the pharmacist and the consumer. Use of a simple screening tool to establish a diagnosis of OA could be used to open up such a dialogue, enabling the pharmacist to educate the customer about the condition, conduct a medication review, provide advice on evidence-based analgesic choices and refer as required. Whilst this strategy may have the potential to bridge the gap between what patients ought to know and what they actually know, research will be needed to determine its uptake and impact on care outcomes.

5 | CONCLUSION

Almost three in five patients with diagnosable OA may not be actively seeking medical care. Pharmacists are a trusted source of advice, are in a unique position to be able to appraise the current medications people are taking and understand the potential for drug–drug interactions; yet, there is evidence of only limited involvement in joint pain management in the community pharmacy setting. Equipping community pharmacists with tools to identify OA
may help to bridge this gap by creating a dialogue about OA. More research is needed to determine if such a strategy would lead to any improvements in consumers’ knowledge or their ability to appropriately manage early OA pain.

ACKNOWLEDGEMENTS
The authors would like to thank consumers living with osteoarthritis (Thomas Buttel, Yarie Nikolic and Julia Lipski) for their review of the study protocol and questionnaire and the participants for their time in completing the study questionnaire. They also acknowledge FiftyFive5 Pty., Ltd. for online programming and data collection and Hazel Palmer MSc, ISMPP CMPP™ of Scriptix Pty., Ltd. for editorial assistance in the preparation of this manuscript, both funded by Bayer Australia Ltd Consumer Healthcare. This study was sponsored by Bayer Australia Ltd., Consumer Healthcare (Study Number BAY-AUS-01), which had input into the concept, study design, data analyses, data interpretation and preparation of this report. The study sponsor markets naproxen (Aleve®). David J. Hunter, Andrew J. McLachlan and Peter R. Carroll received honoraria from Bayer Australia Ltd., Consumer Healthcare for their involvement in an initial working group to determine the parameters of this study project. Tom A. N. Wakefield was compensated for his involvement via FiftyFive5 Pty., Ltd. which was funded by the sponsor to carry out data collection and analysis. The authors were responsible for all content, the interpretation of the data and the decision to publish the results; they received no honoraria related to the development of this manuscript. The sponsor funded editorial assistance and reviewed the final draft before submission. Editorial assistance in the preparation of this manuscript was provided by Hazel Palmer, MSc, ISMPP CMPP™ of Scriptix Pty., Ltd.

CONFLICT OF INTERESTS
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: David J. Hunter reports personal fees and other support from Bayer Australia Ltd., Consumer Healthcare during the conduct of the study and personal fees from Merck Serono, Novartis, Bayer, Tissuegene and TLCBio outside the submitted work. Andrew J. McLachlan reports personal fees and other support from Bayer Australia Ltd., Consumer Healthcare during the conduct of the study and research funding to the Sydney Pharmacy School from GSK to support a PhD scholar under his supervision, outside the submitted work. Peter R. Carroll reports personal fees and other support from Bayer Australia Ltd., Consumer Healthcare during the conduct of the study. Tom A. N. Wakefield reports receiving personal fees from his employer (Fifty Five 5 Pty., Ltd.), who were paid consulting fees by Bayer Australia Ltd., Consumer Healthcare during the conduct of the study and nonfinancial support provided by Bayer Australia Ltd., Consumer Healthcare during the preparation of the manuscript. Rodney Stosic is an employee of Bayer Australia Ltd. Andrew J. McLachlan (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

AUTHOR CONTRIBUTIONS
The following provides a summary of the contributions of each of the authors. David J. Hunter, Andrew J. McLachlan, Peter R. Carroll, Tom A. N. Wakefield and Rodney Stosic conceived the concept of this study and designed the study. David J. Hunter conceived the initial survey questions upon which this study is based; Andrew J. McLachlan, Peter R. Carroll, Tom A. N. Wakefield and Rodney Stosic further refined the survey questions before ethics review and approval. David J. Hunter, Andrew J. McLachlan, Peter R. Carroll and Tom A. N. Wakefield were involved in the conduct of the study; data collection was undertaken by FiftyFive5Pty Ltd. David J. Hunter, Andrew J. McLachlan, Peter R. Carroll and Rodney Stosic guided the analysis of the data and Tom A. N. Wakefield conducted the analysis of the data. David J. Hunter, Andrew J. McLachlan, Peter R. Carroll, Tom A. N. Wakefield and Rodney Stosic contributed to an outline from which the manuscript was drafted. David J. Hunter, Andrew J. McLachlan, Peter R. Carroll, Tom A. N. Wakefield and Rodney Stosic revised the manuscript critically for important intellectual content and gave final approval of the version to be published. Andrew J. McLachlan accepts full responsibility for this study, had access to the data and controlled the decision to publish.

DATA AVAILABILITY STATEMENT
Extra data are available upon reasonable request and with the permission of Bayer Australia Ltd., Consumer Healthcare by emailing: rodney.stosic@bayer.com. A summary report has been provided to the ethics review committee. There are no plans to disseminate the results to the study participants, except upon request.

ORCID
Andrew J. McLachlan https://orcid.org/0000-0003-4674-0242
Peter R. Carroll https://orcid.org/0000-0002-5745-1860
David J. Hunter https://orcid.org/0000-0003-3197-752X
Tom A. N. Wakefield https://orcid.org/0000-0001-7816-6922
Rodney Stosic https://orcid.org/0000-0002-2938-7187

REFERENCES
1. Safiri S, Kolahi A-A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819-828.
2. AIHW. Osteoarthritis. Cat. no. PHE 232. Web report. 2019. Accessed July 15, 2021. https://www.aihw.gov.au/reports/arthritisorother-musculoskeletal-conditions/osteoarthritis/data
40. Brand CA, Harrison C, Tropea J, Hinman RS, Britt H, Bennell K. Management of osteoarthritis in general practice in Australia. Arthritis Care Res. 2014;66(4):551-558.
41. Allen KD, Choong PF, Davis AM, et al. Osteoarthritis: models for appropriate care across the disease continuum. Best Pract Res Clin Rheumatol. 2016;30(3):503-535.
42. Hunter DJ, Bowden JL. Therapy: are you managing osteoarthritis appropriately? Nat Rev Rheumatol. 2017;13(12):703-704.
43. Edwards JJ, Khanna M, Jordan KP, Jordan JL, Bedson J, Dziedzic KS. Quality indicators for the primary care of osteoarthritis: a systematic review. Ann Rheum Dis. 2015;74(3):490-498.
44. Gutterrud Ø, Le C, Pettersen KS, Helseth S, Finbråten HS. Towards a progression of health literacy skills: establishing the HLS-Q12 cutoff scores. Health policy (Amsterdam, Netherlands). 2019.
45. Kao MH, Tsai YF. Living experiences of middle-aged adults with early knee osteoarthritis in prediagnostic phase. Disabil Rehabil. 2012;34(21):1827-1834.
46. Leopoldino AO, Machado GC, Ferreira PH, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2(2):Cd013273.
47. Abdel Shaheed C, Ferreira GE, Dmitritchenko A, et al. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. Med J Aust. 2021;214(7):324-331.
48. Hunter DJ, Bennell K, Austin M, et al. Algorithm—holistic assessment, diagnosis and management of knee and/or hip osteoarthritis. 2018. Accessed July 15, 2021. https://www.racgp.org.au/getattachment/fb2a6a6c2-892a-4ba4-98c2-c984ea25e4a9/Algorithm-Holistic-assessment-diagnosis-and-management-of-knee-and-hip-osteoarthritis.pdf.aspx
49. Sørensen K, Van den Broucke S, Fullam J, et al. Health literacy and public health: a systematic review and integration of definitions and models. BMC Public Health. 2012;12(1):80.
50. Sperber NR, Bosworth HB, Coffman CJ, et al. Differences in osteoarthritis self-management support intervention outcomes according to race and health literacy. Health Educ Res. 2013;28(3):502-511.
51. Gignac MA, Davis AM, Hawker G, et al. "What do you expect? You're just getting older": a comparison of perceived osteoarthritis-related and aging-related health experiences in middle- and older-aged adults. Arthritis Rheum. 2006;55(6):905-912.
52. Bunzl S, O’Brien P, Ayton D, et al. Misconceptions and the acceptance of evidence-based nonsurgical interventions for knee osteoarthritis. A qualitative study. Clin Orthop Relat Res. 2019;477(9):1975-1983.

Additional supporting information may be found in the online version of the article at the publisher’s website.